Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778352 | 0.89 | ALDH1A1 (0.40) | MAPTKCNH2MEN1KMT2AATM | |
| SCHEMBL4773088 | 0.89 | SIGMAR1 (0.36) | MAPTMEN1KMT2ASIGMAR1 | |
| SCHEMBL4773571 | 0.84 | CNR1 (0.48) | CACNA1G | |
| SCHEMBL4778381 | 0.84 | LSS (0.40) | CACNA1GMEN1KMT2ASIGMAR1 | |
| SCHEMBL4776397 | 0.83 | CYP3A4 (0.52) | MAPTKCNH2MEN1KMT2AGAA | |
| SCHEMBL4776514 | 0.81 | SIGMAR1 (0.36) | SIGMAR1 | |
| SCHEMBL4778576 | 0.80 | FAAH (0.47) | KCNH2 | |
| SCHEMBL4771297 | 0.73 | NPSR1 (0.46) | MAPTMEN1KMT2AATM | |
| SCHEMBL4774991 | 0.71 | LMNA (0.39) | MAPTKCNH2SIGMAR1 | |
| SCHEMBL4779187 | 0.70 | MAPT (0.42) | MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |